{"paper_id":"6cd72c3f-b854-469d-b218-cb01529b279e","body_text":"Zusammenfassung\nAuf dem Boden einer Endometriose können maligne Tumoren entstehen; dabei fallen etwa 80 % auf Ovarialkarzinome und etwa 20 % auf extragonadale Manifestationen. Diese maligne Transformation kann jedes Gewebe betreffen, in dem auch Endometriose vorkommt. Eine direkte Kanzerisierung benigner Endometriose über Atypien erscheint möglich. Histologisch handelt es sich bei den endometrioseassoziierten Malignomen überwiegend um endometrioide oder klarzellige Karzinome, seltener um andere histologische Typen, wie seromuzinöse Bordeline-Tumoren, endometriale Stromasarkome, Adenosarkome u. a. Das Risiko einer malignen Transformation von Endometriosegewebe bzw. deren Prävalenz wurde in älteren Arbeiten mit insgesamt 1 % angegeben, bei ovariellen Endometriomen mit 2,5 % bei einer Breite zwischen 2 und 17 %. Molekularbiologisch wurden PTEN- und ARID1a-Mutationen sowie Heterozygotieverlust gefunden. Klinisch wird eine bessere Prognose dieser Tumoren im Vergleich mit high-grade serösen Ovarialkarzinomen diskutiert. Insgesamt liegen in der Literatur nur wenige systematische Studien zu diesen Malignomen vor. Die Stiftung Endometrioseforschung führt gemeinsam mit den Kommissionen Ovar und Uterus der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) aktuell eine retrospektive Studie zur Charakterisierung endometrioseassoziierter Malignome durch (EAM-Studie); ihr Herzstück ist die histopathologische Zweitbegutachtung in einem Referenzlabor.\nAbstract\nMalignant tumors can arise from endometriosis with 80 % presenting as ovarian cancer and 20 % as extragonadal manifestations. This malignant transformation may basically affect every tissue that could potentially harbor endometriosis. A direct cancerous transformation of benign endometriosis through atypias seems to be possible. Histologically, endometriosis-associated malignancies mostly present as endometrioid or clear cell carcinomas, rarely as seromucinous borderline lesions, endometrial stromal sarcomas, adenosarcomas and others. The overall risk of malignancy of endometriosis tissue has been estimated as 1 % and 2.5 % for ovarian endometriomas with a range between 2 % and 17 %. PTEN and ARID1A mutations as well as loss of heterozygosity have been reported as molecular genetic findings. Clinically, a more favorable prognosis of these tumors compared to high-grade serous ovarian cancers is being discussed. There are only few systematic studies concerning these tumors. The Endometriosis Research Foundation together with the study groups on ovarian and uterine tumors of the working group for gynecological oncology (AGO) are currently conducting a retrospective study to characterize endometriosis-associated tumors (EAM study). The core component of the study is the expert histopathological second opinion in a reference laboratory.\nSimilar content being viewed by others\nLiteratur\nAris A (2010) Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res 3:2\nBlaustein (2011) Blaustein’s pathology of the female genital tract. Springer, Berlin Heidelberg New York Tokyo\nBorgfeldt C, Andolf E (2004) Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 83:395–400\nBoyraz G, Selcuk I, Yazicioglu A et al (2013) Ovarian carcinoma associated with endometriosis. Eur J Obstet Gynecol Reprod Biol 170:211–213\nBrooks JJ, Wheeler JE (1977) Malignancy arising in extragonadal endometriosis: a case report and summary of the world literature. Cancer 40:3065–3073\nClement PB (2007) The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol 14:241–260\nCuff J, Longacre TA (2012) Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type. Am J Surg Pathol 36:688–695\nDavis M, Rauh-Hain JA, Andrade C et al (2014) Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol 132:760–766\nDenschlag DM, Manns M, Woll J, Ulrich U (2013) Endometriose und ovarielle Malignome. Frauenarzt 54:570–572\nErzen M, Rakar S, Klancnik B et al (2001) Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 83:100–108\nEskenazi B, Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24:235–258\nGallegos-Arreola MP, Valencia-Rodriguez LE, Puebla-Perez AM et al (2012) The TP53 16-bp duplication polymorphism is enriched in endometriosis patients. Gynecol Obstet Invest 73:118–123\nHeaps JM, Nieberg RK, Berek JS (1990) Malignant neoplasms arising in endometriosis. Obstet Gynecol 75:1023–1028\nHeidemann LN, Hartwell D, Heidemann CH et al (2014) The relation between endometriosis and ovarian cancer – a review. Acta Obstet Gynecol Scand 93:20–31\nHigashiura Y, Kajihara H, Shigetomi H et al (2012) Identification of multiple pathways involved in the malignant transformation of endometriosis (Review). Oncol Lett 4:3–9\nHorn LC, Hentschel B, Meinel A et al (2009) Cyclooxygenase-2 expression, Ki-67 labeling index, and perifocal neovascularization in endometriotic lesions. Ann Diagn Pathol 13:373–377\nKajihara H, Yamada Y, Shigetomi H et al (2012) The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear cell-type versus endometrioid-type adenocarcinoma. Int J Gynecol Pathol 31:304–312\nKim HS, Kim TH, Chung HH et al (2014) Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 110:1878–1890\nKobayashi H, Imanaka S, Nakamura H et al (2014) Understanding the role of epigenomic, genomic and genetic alterations in the development of endometriosis (review). Mol Med Report 9:1483–1505\nKobayashi H, Sumimoto K, Kitanaka T et al (2008) Ovarian endometrioma–risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol 138:187–193\nKommoss S, Pfisterer J, Du Bois A et al (2014) Spezialisierte histopathologische Zweitbegutachtung fortgeschrittener Ovarailkarzinome. Erfahrungen an Kollektiven aus prospektiv randomisierten Phase-III-Studien. Pathologe 35:355–360\nKumar S, Munkarah A, Arabi H et al (2011) Prognostic analysis of ovarian cancer associated with endometriosis. Am J Obstet Gynecol 204:63 e61–67\nMaeda D, Shih Ie M (2013) Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 20:45–52\nMerritt MA, De Pari M, Vitonis AF et al (2013) Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod 28:1406–1417\nModugno F, Ness RB, Allen GO et al (2004) Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 191:733–740\nOrezzoli JP, Russell AH, Oliva E et al (2008) Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol 110:336–344\nPalacios J, Gamallo C (1998) Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 58:1344–1347\nPearce CL, Templeman C, Rossing MA et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13:385–394\nProwse AH, Manek S, Varma R et al (2006) Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 119:556–562\nSamartzis EP, Noske A, Dedes KJ et al (2013) ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci 14:18824–18849\nSato N, Tsunoda H, Nishida M et al (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052–7056\nSayasneh A, Tsivos D, Crawford R (2011) Endometriosis and ovarian cancer: a systematic review. ISRN Obstet Gynecol 2011:140310\nScarfone G, Bergamini A, Noli S et al (2014) Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study. Gynecol Oncol 133:480–484\nSchmidt D, Ulrich U (2014) Endometrioseassoziierte Tumorerkrankungen des Ovars. Pathologe 4:348–354\nSeidman JD (1996) Prognostic importance of hyperplasia and atypia in endometriosis. Int J Gynecol Pathol 15:1–9\nSiufi Neto J, Kho RM, Siufi DF et al (2014) Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer. J Minim Invasive Gynecol 21:55–63\nSomigliana E, Vigano P, Parazzini F et al (2006) Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 101:331–341\nStewart CJ, Leung Y, Walsh MD et al (2012) KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum Pathol 43:1177–1183\nSwiersz LM (2002) Role of endometriosis in cancer and tumor development. Ann N Y Acad Sci 955:281–292 (discussion 293–285, 396–406)\nUlrich U (2013) Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie der Endometriose. In: Zuckschwerdt, München\nUlrich U, Rhiem K, Kaminski M et al (2005) Parametrial and rectovaginal adenocarcinoma arising from endometriosis. Int J Gynecol Cancer 15:1206–1209\nVan Gorp T, Amant F, Neven P et al (2004) Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 18:349–371\nVlahos NF, Kalampokas T, Fotiou S (2010) Endometriosis and ovarian cancer: a review. Gynecol Endocrinol 26:213–219\nWorley MJ, Welch WR, Berkowitz RS et al (2013) Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci 14:5367–5379\nZanetta GM, Webb MJ, Li H et al (2000) Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecol Oncol 79:18–22\nEinhaltung ethischer Richtlinien\nInteressenkonflikt. U. Ulrich gibt an, dass kein Interessenkonflikt besteht. A. Wunschel, V. M. Reichert, S. Darb-Esfahani, D. Denschlag, L.-C. Horn, F. Noack, S. P. Renner, M. Sillem, K.-W. Schweppe, E. Wardelmann, D. Schmidt haben keine Angaben gemacht.\nDieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nUlrich, U., Wunschel, A., Reichert, V. et al. Endometrioseassoziierte maligne Tumoren. Gynäkologe 48, 221–227 (2015). https://doi.org/10.1007/s00129-014-3424-y\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00129-014-3424-y","source_license":"CC0","license_restricted":false}